| Malic enzyme 1 knockout has no deleterious phenotype and is favored in the male germline under standard laboratory conditions JM Alektiar, M Shan, MD Radyk, L Zhang, CJ Halbrook, L Lin, C Espinoza, ... Plos one 19 (6), e0303577, 2024 | 1 | 2024 |
| Cancer Hallmarks: Piecing the Puzzle Together MP Alcolea, D Alonso-Curbelo, C Ambrogio, S Bullman, AL Correia, ... Cancer Discovery 14 (4), 674-682, 2024 | 1 | 2024 |
| Metabolism as a key regulator of macrophage phenotype in pancreatic cancer C Anaraki, C Halbrook Cancer Research 84 (6_Supplement), 1599-1599, 2024 | | 2024 |
| The epigenetic factor BMI1 regulates metabolism and tumorigenesis in human pancreatic cancer cells JN Mills, D Awad, HK Schofield, JK Thompson, H Watkoske, D Sutton, ... Cancer Research 84 (6_Supplement), 4441-4441, 2024 | | 2024 |
| Abstract PR10: Uridine-to-ribose axis supports glucose-restricted pancreatic cancer ZC Nwosu, MH Ward, P Sajjakulnukit, P Poudel, C Ragulan, S Kasperek, ... Cancer Research 84 (2_Supplement), PR10-PR10, 2024 | | 2024 |
| Abstract C024: Single-cell transcriptomics reveals unique stromal and metabolic heterogeneity in liver metastatic pancreatic cancer R Singh, N Yousefian, N Steele, C Halbrook Cancer Research 84 (2_Supplement), C024-C024, 2024 | | 2024 |
| Abstract A056: Targeting the mevalonate biosynthesis pathway in gemcitabine resistant pancreatic cancer AK Beutel, S Calderon, E Nghiem, R Singh, C Anaraki, K Gulay, H Tiriac, ... Cancer Research 84 (2_Supplement), A056-A056, 2024 | | 2024 |
| Uridine Phosphorylase-1 supports metastasis of mammary cancer by altering immune and extracellular matrix landscapes of the lung D Whyte, J Vande Voorde, D Sumpton, S Dhayade, E Dornier, M Moore, ... bioRxiv, 2024.07. 02.601676, 2024 | | 2024 |
| Glucose-6-phosphate dehydrogenase deficiency accelerates pancreatic acinar-to-ductal metaplasia MD Radyk, BS Nelson, CJ Halbrook, A Wood, B Lavoie, L Salvatore, ... bioRxiv, 2023 | 1 | 2023 |
| Uridine-derived ribose fuels glucose-restricted pancreatic cancer ZC Nwosu, MH Ward, P Sajjakulnukit, P Poudel, C Ragulan, S Kasperek, ... Nature 618 (7963), 151-158, 2023 | 45 | 2023 |
| Pancreatic cancer: Advances and challenges CJ Halbrook, CA Lyssiotis, MP di Magliano, A Maitra Cell 186 (8), 1729-1754, 2023 | 308 | 2023 |
| Arginase 1 is a key driver of immune suppression in pancreatic cancer RE Menjivar, ZC Nwosu, W Du, KL Donahue, HS Hong, C Espinoza, ... Elife 12, e80721, 2023 | 41 | 2023 |
| Barriers and opportunities for gemcitabine in pancreatic cancer therapy AK Beutel, CJ Halbrook American Journal of Physiology-Cell Physiology 324 (2), C540-C552, 2023 | 33 | 2023 |
| An Optimized Enzyme-Nucleobase Pair Enables In Vivo RNA Metabolic Labeling with Improved Cell-Specificity MK Singha, J Zimak, SR Levine, N Dai, C Hong, C Anaraki, M Gupta, ... Biochemistry 61 (23), 2638-2642, 2022 | 3 | 2022 |
| Differential stress responses drive asparagine exchange in pancreatic cancer. C Anaraki, G Thurston, NG Steele, SA Kerk, H Hong, P Sajjakulnukit, ... CANCER RESEARCH 82 (22), 64-65, 2022 | | 2022 |
| Deconvoluting the metastatic PDA tumor microenvironment R Singh, C Halbrook, N Steele CANCER RESEARCH 82 (22), 167-168, 2022 | | 2022 |
| Abstract B012: Differential stress responses drive asparagine exchange in pancreatic cancer C Anaraki, G Thurston, NG Steele, SA Kerk, H Hong, P Sajjakulnukit, ... Cancer Research 82 (22_Supplement), B012-B012, 2022 | | 2022 |
| Abstract C083: Deconvoluting the metastatic PDA tumor microenvironment R Singh, C Halbrook, N Steele Cancer Research 82 (22_Supplement), C083-C083, 2022 | | 2022 |
| Abstract PR023: Targeting gemcitabine resistance in pancreatic cancer AK Beutel, R Singh, C Anaraki, G Tong, T Martinez, A Kleger, Z Jutric, ... Cancer Research 82 (22_Supplement), PR023-PR023, 2022 | | 2022 |
| Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells CJ Halbrook, G Thurston, S Boyer, C Anaraki, JA Jiménez, A McCarthy, ... Nature cancer 3 (11), 1386-1403, 2022 | 27 | 2022 |
